CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cheaper generic breast cancer drug put to the test
Disease control OngoingThis study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …
Matched conditions: CDK4/6 INHIBITOR
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to predict dangerous side effects of common breast cancer drugs
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 100 breast cancer patients taking CDK4/6 inhibitor drugs. Researchers want to find genetic and blood markers that can predict who will have bad side effects or not get enough benefit from the medication. The goal is to help doctors choose safer and more effect…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC